Analysis of the effects and prognosis using nafamostat and sodiuml citrate anticoagulant in sepsis patients with CRRT
Objective To evaluate the effects of nafamostat and sodiuml citrate anticoagulant on the survival rate and the anticoagulant effectiveness of continuous renal replacement therapy in patients with sepsis.Methods Collect the clinical data of patients suffered from both sepsis and acute kidney injury,who received CRRT and were treated with nafamostat and sodiuml citrate anticoagulant in Tai'an Central Hospital from May 2022 to September 2023.The nafamostat group and sodiuml citrate anticoagulant group were set up to analyze the following indexes:the general situations,the IL-6 of 24 hours after CRRT treatment,the time it takes for the PCT to fall into the normal range in surviving patients,the 7-day、14-day、21-day and 28-day survival rate,the total quantity and whole time of filter,the the lifespan of the first CRRT filter in 72 hours by retrospective analysis.Results Our study involved the total of 67 patients,of which 31 were divided into nafamostat group and 36 were divided into sodiuml citrate anticoagulant group.There was no significant difference in general information between the two groups(P＞0.05).The IL-6 of nafamostat group was significantly lower than that of insodiuml citrate anticoagulant group after 24 hours of CRRT(Z=-3.282,P＜0.05).The time required for PCT to decline to the normal range after treatment was significantly shorter in the nafamostat group than in the sodium citrate anticoagulant group[(10.16±1.55)d vs.(12.55±2.26)d,P＜0.05].Kaplan-Meier survival analysis showed that the 28-day survival rate of patients in the nafamostat group was significantly higher than that in the sodiuml citrate anticoagulant group(P＜0.05),nevertheless no significant difference existed between the 7-day、14-day and 21-day survival rate.There was no significant difference in the first filter life of CRRT between the two groups[(49.81±3.45)h vs.(45.36±2.83)h,P＞0.05],and also no significant difference were found in the total quantity and the whole time of the filter(P＞0.05).Conclusion When sepsis was integrated with AKI requiring CRRT treatment,nafamostat was more effective than sodium citrate anticoagulant in clearing inflammatory mediators and improving survival prognosis of patients,but there was no significant difference in the effects of the two anticoagulants on filter life.
NafamostatSodiuml citrate anticoagulantSepsis with acute kidney injurySurvival rate
万方数据
维普
